Sebastian Ochsenreither

Title: Innovations in Cancer Immunotherapy by Sebastian Ochsenreither

Introduction

Sebastian Ochsenreither is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of cancer immunotherapy, particularly through his innovative approaches targeting specific antigens associated with leukemia.

Latest Patents

Ochsenreither holds a patent for "Cyclin A1-targeted T-cell immunotherapy for cancer." This patent describes compositions and methods designed to elicit antigen-specific T-cell responses against human cyclin A1 (CCNA1). CCNA1 is identified as a leukemia-associated antigen due to its overexpression in acute myeloid leukemia (AML), including leukemia stem cells (LSC) and immunologically privileged testis cells, while being absent in other normal cell types. The patent also discloses CCNA1-derived peptide epitopes that are immunogenic for T-cells, including cytotoxic T lymphocytes (CTL). Furthermore, it outlines immunotherapeutic approaches utilizing these peptides for vaccines and the generation of adoptive transfer therapeutic cells.

Career Highlights

Throughout his career, Sebastian Ochsenreither has worked with prestigious institutions such as the Fred Hutchinson Cancer Center and the Fred Hutchinson Cancer Research Center. His work has focused on advancing the understanding and treatment of cancer through innovative immunotherapeutic strategies.

Collaborations

Ochsenreither has collaborated with notable professionals in the field, including Philip D. Greenberg. Their joint efforts have contributed to the development of cutting-edge therapies aimed at improving patient outcomes in cancer treatment.

Conclusion

Sebastian Ochsenreither's work in cancer immunotherapy exemplifies the potential of targeted treatments in combating leukemia. His innovative patent and collaborations highlight the importance of research and development in the fight against cancer.